Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne muscular dystrophy. EXG-7001 is a locally administered, full-length dystrophin mRNA therapeutic that is currently in preclinical development for the treatment of Duchenne muscular dystrophy.